Adults with atopic dermatitis (AD) stay on dupilumab (Dupixent, Sanofi and Regeneron) significantly longer than on cyclosporine, according to a recent study.
Across all doses, lebrikizumab showed significant dose-dependent improvement in primary study endpoints for improvements in atopic dermatitis, according to data from phase 2b trials.
In clinical trials, most patients treated with tralokinumab maintained 75% reductions in EASI scores for one year.
Vehicles for topical atopic dermatitis treatments deliver benefits that promote barrier restoration and enhance innate immune defenses, a review suggests.
Tape strips outperformed skin biopsies by differentiating eczema from psoriasis with high accuracy, researchers report.
The U.S. Food and Drug Administration (FDA) has granted JAK-inhibitor delgocitinib cream (LEO Pharma) Fast Track Designation for chronic hand eczema.
Gain insight from the experts on current and future treatment for pediatric atopic dermatitis.
The U.S. Food and Drug administration has accepted the Biologics License Application for tralokinumab (LEO Pharma) for moderate-to-severe atopic dermatitis and is expected to make a decision in the second quarter of 2021.
Researchers of a recent systematic review and meta-analysis examine how dupilumab compares to older systemic treatments for atopic dermatitis, including methotrexate, cyclosporine and azathioprine.
The U.S. Food and Drug Administration has approved a single-dose 300 mg pre-filled pen version of dupilumab (Dupixent, Sanofi and Regeneron) for the treatment of atopic dermatitis, asthma and chronic rhinosinusitis with nasal polyposis (CRSwNP) in U.S. patients 12 years and older.